We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Artificial Intelligence Method That Improves Lab Test Management Discussed at AACC 2021

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021
Print article
Illustration
Illustration

Results from an evaluation of an artificial intelligence (AI) method that improves test utilization and reimbursement were presented by Patients Choice Laboratories (Indianapolis, IN, USA) at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

Of the five billion lab orders submitted each year, at least 20% are considered inappropriate. These inappropriate tests can lead to slower or incorrect diagnoses for patients. Such tests may also not be covered by Medicare if they weren’t meant to be used for particular medical conditions or if they were ordered with the wrong ICD-10 diagnostic codes, which in turn raises health costs.

Patients Choice Laboratories set out to determine if an automated test management system known as the Laboratory Decision System (LDS) could help improve test ordering. The LDS scores potential tests based on medical necessity and testing indication, helping providers minimize test misutilization and select the best tests for a given medical condition.

Using LDS, the researchers re-evaluated a total of 374,423 test orders from a reference laboratory, 48,049 of which had not met the criteria for coverage under Medicare. For 96.4% of the first 10,000 test claims, the LDS ranking system recommended alternative tests that better matched the medical necessity or had a more appropriate ICD-10 code. Of these recommendations, 80.5% would also meet Medicare policies. All of this indicates that the LDS could help correct mistaken or inappropriate lab orders.

“Our study implies that use of the automated test ordering system LDS would be extremely helpful for providers, laboratories, and payers,” said Dr. Rojeet Shrestha, PhD, of Patients Choice Laboratories. “Use of this algorithm-based testing selection and ordering database, which rates and scores potential tests for any given disease based on clinical relevance, medical necessity, and testing indication, would eventually help providers to select and order the right test and reduce over- and under-utilization of tests.”

Related Links:
Patients Choice Laboratories

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more